Individuals Stopping Slimming Jabs Regain Pounds Far More Rapidly Compared to Those on Conventional Diets

Fresh analysis suggests that patients who stop using popular GLP-1 drugs like semaglutide or tirzepatide may regain lost weight much more quickly than those who end conventional diet and exercise plans.

Published data in a prominent medical journal demonstrates that while overweight people can lose a large proportion of their total mass while on the medication, the mass returns at an average rate of nearly a kilo each month once they quit.

"Individuals buying such treatments should be aware of the risk of quick rebound weight gain when the therapy ends," warns researcher Dr. Susan Jebb.

Such speed of regain means a reversion to original weight in about a year and a half.

Comparing Treatments

The analysis, which reviewed dozens of trials involving over 9,000 of participants, contrasted the outcomes of GLP-1 agonists with other pills.

Researchers emphasize that individuals who lose weight through dieting typically experience a slower creep back—around 0.1 kg a month—post-intervention.

The Reason for the Quick Regain

Experts suggest the mechanism of the injections accounts for the heightened rebound.

GLP-1 drugs copy a natural hormone called GLP-1, which helps regulate feelings of fullness.

"Sustained high doses of the hormone levels several times higher than the body's typical production could lead to the body to generate a reduced amount of its own natural hormone, and may also reduce responsiveness to its effects," explained Dr. Adam Collins, a nutrition expert.

"Discontinuation of this GLP-1 'fix' results in hunger is unsuppressed, making excessive eating a significant risk."

A Lifelong Issue?

The NHS recommend the jabs for people with obesity-related health risks, alongside recommended lifestyle changes.

Professionals say that, given the likelihood of relapse, the therapy should be considered life-long.

This perspective is reinforced by drug manufacturers, who say that the findings "underscore the long-term nature of excess weight," comparing it to managing diseases like high blood pressure.

User Accounts

Users who have discontinued the medication report a intense resurgence of hunger.

"It felt as if a switch activating and you're instantly ravenous," described a patient.

The struggle is worsened if users have not developed permanent dietary or behavioural changes during therapy.

Significant Interest

Survey data suggest that a significant number of adults in the UK have used weight-loss jabs in the last 12 months, with desire remaining high.

• Use is greater among women than males.
• The middle-aged demographic shows the greatest usage rates.
• A large proportion access the medications through private healthcare rather than public health services.

Finally, clinicians stress that while the jabs are potent agents for shedding pounds, they are not a standalone fix and maintained weight loss likely depends on ongoing lifestyle changes.